Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1

NCT07024394 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

65

Enrollment

INDUSTRY

Sponsor class

Conditions

Neurofibromatosis 1
Plexiform Neurofibroma
NF1

Interventions

DRUG: Luvometinib Tablets

Sponsor

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.